Target intelligence / Profile preview

Saccharomyces cerevisiae var. boulardii (S. boulardii)

Target
S. boulardii
Molecular classification
Fungus, Yeast, Ascomycota (Phylum), Saccharomycetes (Class), Saccharomycetales (Order)
01

Overview

Probiotic yeast typically refers to Saccharomyces cerevisiae var. boulardii, a live, non-pathogenic yeast strain well-studied for its ability to protect and restore gut microbiota, inhibit harmful pathogens, regulate immune responses, and promote intestinal health. It is classified taxonomically as a member of the yeast kingdom, specifically the genus Saccharomyces and the species S. cerevisiae (with boulardii as a variant/strain). Its use as a probiotic is mainly in gastrointestinal disorders; it is not a molecular target but functions as a living therapeutic microorganism. While clinical studies support its safety and efficacy for most populations, caution is advised in immunocompromised individuals due to risk of systemic infection.

Other names
Saccharomyces boulardiiS. boulardiiSaccharomyces cerevisiae var. boulardiiprobiotic Saccharomycesprobiotic yeast
02

Mechanism of action

Competitive exclusion of pathogenic microbes; Neutralization of bacterial toxins; Production of bioactive metabolites with antimicrobial properties; Enhancement of mucin and barrier protective mechanisms; Immunomodulation by stimulating cytokine and immunoglobulin production.

03

Biological functions

Restoration of normal gut microbiotaInhibition of pathogenic microbesModulation of the immune system (cytokine production, regulation of inflammation)Trophic effects on intestinal epitheliumEnhancement of intestinal barrier functionPromotion of digestive enzyme and nutrient transporter synthesis
04

Disease associations

Infection (acute diarrhea, antibiotic-associated diarrhea, Clostridioides difficile infection)Inflammatory bowel diseases (e.g., ulcerative colitis, Crohn's disease)Prevention of allergies and asthma (based on animal models)Other gastrointestinal disorders (constipation, irritable bowel syndrome)
05

Safety considerations

Potential for fungemia in immunocompromised patients (rare)Possible allergic reactions (rare)Should be used with caution in seriously ill, immunocompromised, or hospitalized individuals
06

Biomarkers

None widely established for patient selection or efficacy; outcomes monitored are generally clinical (e.g., resolution of diarrhea)

Beyond the preview

Go deeper on Saccharomyces cerevisiae var. boulardii (S. boulardii).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saccharomyces cerevisiae var. boulardii (S. boulardii).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call